Prokaryotics Inc. develops novel antibiotics targeting bacterial cell envelope biogenesis to combat multidrug-resistant infections. The company focuses on pre-clinical assets that address the global crisis of antibiotic resistance, leveraging expertise in bacterial physiology and medicinal chemistry.
Funding
$2.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
The rise of multidrug-resistant bacteria poses a significant threat to global health, as existing antibiotics become ineffective against increasingly resistant strains. Traditional antibiotics often fail to address infections caused by bacteria with robust cell envelopes, which act as a barrier against many drugs.
Solution
Prokaryotics Inc. is developing a pipeline of novel antibiotics designed to overcome bacterial resistance by targeting cell envelope biogenesis. The company's pre-clinical assets focus on inhibiting essential enzymes involved in bacterial cell envelope assembly, a process critical for bacterial survival and virulence. By targeting this fundamental process, Prokaryotics aims to create new classes of antibiotics that can effectively combat both Gram-negative and Gram-positive bacteria, including those resistant to existing treatments. Their approach seeks to develop agents with improved efficacy and safety profiles against a broad spectrum of resistant bacteria.
Target Audience
The primary target audience includes patients at risk of or infected with multidrug-resistant bacterial infections, as well as healthcare providers seeking novel therapeutic options to combat these infections.
Features
- Focus on small molecule inhibitors targeting MsbA-mediated transport and biogenesis of lipopolysaccharide (LPS) in Gram-negative bacteria.
- Development of β-lactam potentiators to restore the efficacy of commonly used β-lactams against MRSA.
- Programs targeting glucosylphosphatidyl inositol (GPI) cell wall biosynthesis in fungal infections.
- Combination product development pairing novel bacterial cell wall inhibitors with polymyxin cell envelope permeabilizers to treat Acinetobacter baumannii infections.
- Novel compounds for use as adjuvants to restore the efficacy of commonly used β-lactams against MRSA.